CJC-1295 (No DAC) + Ipamorelin 5mg Blend is a dual-component research peptide formulation supplied for controlled laboratory, biochemical and analytical investigation. The combination brings together a GHRH-related research peptide with Ipamorelin, a synthetic pentapeptide growth hormone secretagogue, for experimental research involving receptor signalling, endocrine molecular pathways, peptide interactions and analytical characterisation.
The 5mg designation represents the stated research quantity and is not a dosage recommendation.
For Research Use Only – Not for human or veterinary consumption.
Price range: $67.69 through $94.76
CJC-1295 (No DAC) + Ipamorelin 5mg Blend from Axion Peptide Lab is a specialised dual-component peptide formulation supplied exclusively for controlled laboratory, biochemical and analytical research.
The formulation combines a CJC-1295 No DAC research component with Ipamorelin, allowing qualified researchers to investigate two distinct peptide signalling approaches within a single experimental format.
CJC-1295-related materials are associated with growth hormone-releasing hormone (GHRH) pathway research, while Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue.
The combination is therefore of interest in experimental research examining peptide signalling, receptor interactions, endocrine molecular pathways and comparative peptide activity.
Importantly, the term “No DAC” distinguishes this research material from long-acting CJC-1295 containing a Drug Affinity Complex. Published findings involving DAC-modified CJC-1295 should not automatically be attributed to the No DAC material.
The 5mg designation identifies the stated quantity associated with the research blend and is not a dosage or administration recommendation.
For Research Use Only – Not for human or veterinary consumption.
CJC-1295 (No DAC) + Ipamorelin is a two-component research peptide formulation designed for laboratory investigation of complementary signalling pathways.
CJC-1295-related peptides are derived from growth hormone-releasing hormone research and are investigated for their interaction with GHRH-associated signalling systems.
Ipamorelin belongs to another research category. It is a synthetic pentapeptide originally developed and investigated as a selective growth hormone secretagogue.
Combining the two materials provides researchers with a convenient experimental format for investigating interactions between different signalling mechanisms.
The blend itself should not be treated as a newly created single peptide molecule. It contains two distinct research components, and findings involving either component individually cannot automatically be attributed to the combined formulation.
The terminology surrounding CJC-1295 requires particular care.
The original CJC-1295 described in scientific literature contains a modification designed to bind to albumin, significantly extending its biological persistence. This is generally associated with the DAC form.
Commercial research terminology also uses CJC-1295 No DAC for shorter-acting GHRH-related peptide material without the Drug Affinity Complex.
Researchers should therefore avoid assuming that pharmacokinetic properties reported for long-acting CJC-1295 apply directly to the No DAC material.
Exact molecular identity should always be confirmed using documentation associated with the specific research product and batch.
This distinction is particularly important when designing analytical, stability or comparative peptide experiments.
Ipamorelin is a synthetic peptide containing five amino-acid residues and is therefore classified as a pentapeptide.
Published research describes its sequence as:
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Ipamorelin was developed as a growth hormone secretagogue and has been investigated experimentally for its ability to interact with secretagogue-associated receptor pathways.
Early pharmacological research examined Ipamorelin in cellular and animal models, while a human volunteer study investigated its pharmacokinetic and pharmacodynamic characteristics.
For researchers, Ipamorelin provides an experimental molecule for studying peptide-receptor interactions, endocrine signalling and related molecular mechanisms.
These research findings do not establish the Axion Peptide Lab material as a therapeutic product.
One reason researchers may investigate CJC-1295 No DAC and Ipamorelin together is that the two components are associated with different signalling mechanisms.
GHRH-related peptides are studied through GHRH receptor pathways.
Growth hormone secretagogues such as Ipamorelin have been investigated through secretagogue-associated receptor mechanisms.
A dual-component formulation may therefore allow researchers to examine how two signalling approaches behave when studied under the same experimental conditions.
Potential laboratory designs may compare the combined material with individual-component controls.
Such comparative research can help determine whether observations are associated with one component, both components independently or interactions occurring within the experimental system.
Growth hormone-releasing hormone is an important signalling peptide within endocrine biology.
GHRH-related peptides have consequently been investigated in molecular, receptor and pituitary research.
CJC-1295-related compounds emerged from efforts to modify GHRH-derived structures and investigate their stability and signalling characteristics.
Researchers working with a No DAC material may examine molecular identity, peptide-receptor interactions, analytical behaviour or other GHRH-related endpoints.
However, the precise experimental characteristics of a No DAC product should be established from its actual molecular specification rather than inferred from studies involving DAC-modified CJC-1295.
Ipamorelin belongs to the growth hormone secretagogue class of experimental peptides.
Research has examined the interaction between secretagogues and receptors involved in endocrine signalling.
Ipamorelin attracted particular scientific interest because early studies characterised it as a relatively selective secretagogue within the experimental models examined.
Laboratories may investigate receptor activation, downstream signalling, molecular interactions or comparative activity alongside other secretagogue peptides.
These investigations are useful for understanding peptide pharmacology but do not establish a consumer or therapeutic indication for the research material.
Receptor biology is another potential research application for this blend.
Peptides exert many experimental effects through interactions with receptors located on or within cells.
Researchers can use receptor assays and suitable cellular models to examine signalling events following experimental exposure.
A two-component formulation introduces additional questions because each material may interact with a different receptor system.
Individual-component controls can therefore be particularly valuable when analysing results.
Carefully designed studies may improve understanding of how multiple peptide-associated pathways behave under controlled experimental conditions.
CJC-1295-related compounds and Ipamorelin are frequently discussed in connection with endocrine signalling research.
Laboratories studying these systems may investigate biochemical markers, receptor pathways and signalling responses.
Experimental models may also compare different peptide structures or combinations.
Researchers should distinguish clearly between observations made in molecular or animal models and clinically validated human applications.
Recent scientific reviews continue to describe many growth-hormone-axis peptides marketed online as investigational, with important gaps in human safety and efficacy evidence.
This makes accurate research-only positioning particularly important.
CJC-1295 No DAC and Ipamorelin have substantially different molecular structures.
These differences provide opportunities for structure-function investigation.
Researchers may examine how peptide length, amino-acid composition and structural modifications influence molecular behaviour.
Comparative experiments may evaluate individual components alongside related peptides.
Laboratories can also investigate whether combining structurally different peptides affects analytical behaviour or experimental stability.
Structure-function research is valuable for understanding fundamental peptide chemistry without assuming therapeutic effectiveness.
Peptide stability is an important consideration in laboratory research.
Researchers may investigate the individual components or combined formulation under carefully controlled experimental conditions.
Potential endpoints include degradation profiles, peptide integrity, chromatographic behaviour and time-dependent molecular changes. CJC-1295 No DAC + Ipamorelin 5mg
Multi-component blends can introduce additional analytical complexity because individual peptides may display different stability characteristics.
Researchers should therefore document experimental conditions carefully.
Storage requirements and stability characteristics should be taken from product-specific documentation rather than copied from unrelated products. CJC-1295 No DAC + Ipamorelin 5mg
Analytical research can help laboratories understand the composition and molecular characteristics of peptide blends.
Depending on laboratory capabilities, suitable techniques may be used to investigate component identity, chromatographic profiles, molecular mass or degradation products.
Accurate characterisation is particularly important when terminology such as “CJC-1295 No DAC” can be used differently across the research marketplace.
Researchers requiring a particular molecular sequence, salt form, purity or component ratio should verify those specifications using documentation associated with the actual Axion Peptide Lab product and batch.
The 5mg research format provides a clearly identified quantity for controlled laboratory use.
Researchers should confirm the exact amount of each individual component from the product specifications or Certificate of Analysis associated with the relevant batch.
The 5mg designation should not be interpreted as a human dosage.
Experimental quantities should be determined according to validated research protocols, analytical requirements and institutional procedures. CJC-1295 No DAC + Ipamorelin 5mg
Axion Peptide Lab does not provide personal-use, self-administration or human dosing instructions.
CJC-1295 No DAC + Ipamorelin may be relevant to controlled investigation involving:
These are research categories rather than medical indications or promised outcomes.
Accurate documentation is essential when working with research peptides.
Researchers should record product identity, component specifications, batch information and experimental conditions.
For a two-component blend, researchers may also need to know the precise quantity and molecular identity of each component.
Availability of Certificates of Analysis or independent analytical testing may vary according to product and batch. CJC-1295 No DAC + Ipamorelin 5mg
Researchers requiring particular specifications should review available documentation before incorporating the material into experimental workflows.
Claims such as exact purity percentages should only be published when supported by documentation for the relevant batch. CJC-1295 No DAC + Ipamorelin 5mg
This material should be handled only by appropriately trained personnel within controlled research environments.
It should remain clearly labelled and separated from medicines, foods, supplements and consumer products. CJC-1295 No DAC + Ipamorelin 5mg
Researchers should follow laboratory procedures designed to maintain material integrity and minimise contamination.
Product-specific storage and handling requirements should be obtained from the relevant documentation.
Customers are responsible for determining whether acquisition, possession, importation and research use comply with applicable laws and institutional policies. CJC-1295 No DAC + Ipamorelin 5mg
Axion Peptide Lab supplies specialised peptide materials intended for controlled laboratory, biochemical and analytical investigation.
The CJC-1295 No DAC + Ipamorelin blend provides researchers with a convenient two-component format for experimental peptide research.
Clear research-only positioning helps distinguish the product from medicines, supplements and products intended for personal administration.
Researchers should review available product documentation and specifications before ordering to determine whether the material meets their experimental requirements. CJC-1295 No DAC + Ipamorelin 5mg
Qualified laboratories, researchers and scientific organisations can buy CJC-1295 (No DAC) + Ipamorelin 5mg Blend from Axion Peptide Lab for legitimate laboratory and analytical research.
The combination provides a specialised format for research involving GHRH-associated pathways, growth hormone secretagogue signalling, receptor interactions and comparative peptide biology.
Researchers should verify the precise component specifications before incorporating the blend into an experimental protocol. CJC-1295 No DAC + Ipamorelin 5mg
The product is not intended to diagnose, treat, cure or prevent disease and should not be marketed for bodybuilding, performance enhancement or personal administration.
For Research Use Only – Not for human or veterinary consumption.
It is a dual-component research peptide formulation containing CJC-1295 No DAC-related material and Ipamorelin for controlled laboratory and analytical investigation. CJC-1295 No DAC + Ipamorelin 5mg
“No DAC” indicates that the research material does not contain the Drug Affinity Complex associated with long-acting CJC-1295. Researchers should verify the precise molecular identity from product-specific documentation.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue investigated experimentally in receptor and endocrine signalling research. CJC-1295 No DAC + Ipamorelin 5mg
No. Published long-acting CJC-1295 incorporates a modification designed for albumin binding. Results involving that form should not automatically be applied to No DAC material.
Potential areas include GHRH pathways, secretagogue signalling, peptide-receptor interactions, endocrine molecular pathways, structure-function relationships and analytical characterisation. CJC-1295 No DAC + Ipamorelin 5mg
It identifies the stated quantity associated with the research product. It is not a human dosage recommendation.
No. It is a formulation containing two distinct research peptide components.
Current evidence for the combination is limited, and recent reviews continue to characterise CJC-1295 and Ipamorelin-type applications as investigational.
No. The product is intended strictly for laboratory research, and human dosing or self-administration guidance is not provided.
Qualified research customers can purchase the blend from Axion Peptide Lab for legitimate laboratory and analytical investigation, subject to availability and applicable requirements.
